Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

#2106

Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.

Aim(s): To describe treatment patterns of LA-SSA in patients with metastatic GEP-NET G1/G2 in Sweden.

Materials and methods: Data was obtained via linkage of nationwide registers. Patients diagnosed between 1Jul2005 and 31Dec2013 were included. Patients who purchased LA-SSA continuously during at least one year were included (n=300).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Björstad �, Granfeldt D, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, somatostatin analogues, treatment,